Adults with Type 2 diabetes or heart disease who took Abbott Laboratories' weight-loss drug Meridia for nearly 3.5 years had a 28% increased risk of nonfatal heart attack and a 36% higher risk of nonfatal stroke compared with those given placebo during a company-funded study. However, Meridia did not appear to increase the risk of death in patients with a history of cardiovascular disease.

Full Story:
HealthDay News

Related Summaries